Related Experiment Video
Updated: Dec 10, 2025
Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
Published on: September 20, 2016
HER2 Exon 20 Insertion Mutations in Lung Adenocarcinoma: Case Series and Response to Pyrotinib
Xinyong Zhang1, Jialin Lv1, Yuhua Wu1
1Department of Medical Oncology, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing Chest Hospital, Capital Medical University, Beijing, China.
Abstract:
HER2 mutations have emerged as oncogenic driver gene mutations in non-small cell lung cancer (NSCLC), which have not been described in detail like other driver gene mutations. Here, 295 patients with advanced lung adenocarcinoma were retrospectively screened for HER2 mutations using next-generation sequencing (NGS), and the positive cases were validated by Sanger sequencing. We identified five cases with HER2 exon 20 insertions, representing 1.7% of 295 lung adenocarcinomas. Among them, four different subtypes of HER2 exon 20 insertions were identified, including a rare subtype G778_S779insCPG never reported before with a partial response (PR) to pyrotinib and progression-free survival (PFS) of 12.8 months. Our findings reveal that HER2 exon 20 insertion mutations were detected in a small subset of lung adenocarcinomas. Given the different drug sensitivities, determining the mutation subtype by next-generation sequencing at the time of diagnosis might make sense.
Insights
HER2 mutations, particularly exon 20 insertions, are found in a small fraction of non-small cell lung cancer (NSCLC) patients. Identifying specific HER2 mutation subtypes is crucial for targeted therapy selection and improved outcomes.
Area of Science:
- Oncology
- Genetics
- Molecular Biology
Background:
- HER2 mutations are emerging as key oncogenic drivers in non-small cell lung cancer (NSCLC).
- Detailed characterization of HER2 mutations, especially exon 20 insertions, is less established compared to other driver mutations.
- Understanding these mutations is critical for developing effective targeted therapies in lung adenocarcinoma.
Purpose of the Study:
- To investigate the prevalence and subtypes of HER2 mutations in advanced lung adenocarcinoma.
- To identify novel HER2 exon 20 insertion subtypes and assess their response to targeted therapies.
- To evaluate the clinical significance of precise HER2 mutation subtyping for treatment decisions.
Main Methods:
- Retrospective screening of 295 advanced lung adenocarcinoma patients using next-generation sequencing (NGS).
- Validation of identified HER2 mutations via Sanger sequencing.
- Analysis of clinical response, including partial response (PR) and progression-free survival (PFS), to pyrotinib for a novel mutation subtype.
Main Results:
- HER2 exon 20 insertions were identified in 1.7% (5 out of 295) of lung adenocarcinomas.
- Four distinct HER2 exon 20 insertion subtypes were observed, including a novel G778_S779insCPG.
- The novel G778_S779insCPG subtype showed a partial response to pyrotinib with a PFS of 12.8 months.
Conclusions:
- HER2 exon 20 insertion mutations represent a rare but significant subset of lung adenocarcinomas.
- The diverse nature of these mutations suggests varying sensitivities to targeted agents.
- Next-generation sequencing for precise HER2 mutation subtyping at diagnosis is recommended to guide personalized treatment strategies.
More Related Videos
09:38Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
09:38Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
